These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10469284)

  • 1. A dose-finding study of zoledronate in hypercalcemic cancer patients.
    Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
    J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical research update: zoledronate.
    Body JJ
    Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
    Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
    J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
    Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
    Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
    Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
    J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
    Body JJ; Dumon JC; Piccart M; Ford J
    J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
    Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.